<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37460249</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Differential expression of IFN-&#x3b1;, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000962</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000962</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Since molecularly targeted therapies are emerging for treating lupus nephritis (LN), this study aimed to assess the immunohistochemical findings of the cytokines in renal tissue and their pathological and clinical relevance in LN.</AbstractText><AbstractText Label="METHODS">Fifty patients with proliferative LN formed the case group; 5 with LN class II, IgA nephropathy and 10 with idiopathic haematuria were enrolled as controls. Immunohistochemical analysis for CD3, CD20, interferon (IFN)-&#x3b1;, interleukin (IL)-12/p40 and B-cell activating factor (BAFF) was performed by scoring the number of positive cells/area of the cortex. All immunohistochemical investigations were performed on formalin-fixed paraffin-embedded renal tissue. Proliferative LN cases were grouped by the dominant expression of IFN-&#x3b1;, IL-12/p40 and BAFF, and subsequently, clinicopathological features were compared.</AbstractText><AbstractText Label="RESULTS">Clinical data of patients with proliferative LN included urine protein creatinine ratio, 2.2 g/gCre; anti-double-stranded DNA antibody, 200.9 IU/mL; total complement activity (CH50), 21.9 U/mL and SLE Disease Activity Index, 19.8 points. Proliferative LN cases, including class III (n=18) and IV (n=32), were classified into three subgroups according to the immunohistochemical score based on the dominancy of IFN-&#x3b1; (n=17), IL-12 (n=16) and BAFF group (n=17) proteins. Hypocomplementaemia and glomerular endocapillary hypercellularity were significantly increased in the IFN-&#x3b1; group, whereas chronic lesions were significantly higher in the IL-12 group (p&lt;0.05). The IFN-&#x3b1; group had a poorer renal prognosis in treatment response after 52 weeks.</AbstractText><AbstractText Label="CONCLUSIONS">The immunohistochemistry (IHC) of IFN-&#x3b1;, IL-12 and BAFF for proliferative LN enabled grouping. Especially, the IFN-&#x3b1; and IL-12 groups showed different clinicopathological features and renal prognoses. The results indicated the possibility of stratifying cases according to the IHC of target molecules, which might lead to precision medicine.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nawata</LastName><ForeName>Aya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7871-2425</Identifier><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Oncology, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayamada</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hisano</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Tetsu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kidney Center, University of Occupational and Environmental Health Hospital, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiba</LastName><ForeName>Eisuke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hisaoka</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Oncology, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0807-7139</Identifier><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan tanaka@med.uoeh-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>187348-17-0</RegistryNumber><NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053264">B-Cell Activating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053264" MajorTopicYN="N">B-Cell Activating Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword></KeywordList><CoiStatement>Competing interests: SN has received consulting fees, speaking fees and/or honoraria from Bristol-Myers, AstraZeneca, Pfizer, GlaxoSmithKline, Astellas, Asahi-kasei, Sanofi, AbbVie, Eisai, Chugai, Gilead and Boehringer Ingelheim and has received research grants from Mitsubishi-Tanabe. YT has received speaking fees and/or honoraria from Behringer-Ingelheim, Eli Lilly, AbbVie, Gilead, AstraZeneca, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Pfizer, Mitsubishi-Tanabe and GlaxoSmithKline, and has received research grants from Asahi-Kasei, AbbVie, Chugai, Eisai, Takeda, Daiichi-Sankyo and Behringer-Ingelheim.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>18</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>21</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37460249</ArticleId><ArticleId IdType="pmc">PMC10357699</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000962</ArticleId><ArticleId IdType="pii">10/2/e000962</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parikh SV, Almaani S, Brodsky S, et al. . Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 2020;76:265&#x2013;81. 10.1053/j.ajkd.2019.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, et al. . American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797&#x2013;808. 10.1002/acr.21664</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, et al. . Update of the joint European League against rheumatism and European renal Association-European dialysis and transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79(Suppl 1):1028. 10.1136/annrheumdis-2020-eular.3936</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-eular.3936</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Caster DJ, Cattran DC, et al. . Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney International 2019;95:281&#x2013;95. 10.1016/j.kint.2018.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.11.008</ArticleId><ArticleId IdType="pubmed">30665569</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M, Zen M, Iaccarino L, et al. . New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019;15:30&#x2013;48. 10.1038/s41584-018-0133-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0133-2</ArticleId><ArticleId IdType="pubmed">30538302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis 2020;23:465&#x2013;71. 10.1111/1756-185X.13817</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13817</ArticleId><ArticleId IdType="pmc">PMC7187183</ArticleId><ArticleId IdType="pubmed">32134201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson C, Henderson RB, Jones-Leone AR, et al. . The role of baseline Blys levels and type 1 interferon-inducible gene signature status in determining Belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Arthritis Res Ther 2020;22:102. 10.1186/s13075-020-02177-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02177-0</ArticleId><ArticleId IdType="pmc">PMC7197114</ArticleId><ArticleId IdType="pubmed">32366280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollars E, Bienkowska J, Czerkowicz J, et al. . BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci Med 2015;2:e000063. 10.1136/lupus-2014-000063</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000063</ArticleId><ArticleId IdType="pmc">PMC4477150</ArticleId><ArticleId IdType="pubmed">26113988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Teng YKO, et al. . A secondary analysis of the Belimumab international study in lupus nephritis trial examined effects of Belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney International 2022;101:403&#x2013;13. 10.1016/j.kint.2021.08.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.08.027</ArticleId><ArticleId IdType="pubmed">34560137</ArticleId></ArticleIdList></Reference><Reference><Citation>Samotij D, Reich A. Biologics in the treatment of lupus erythematosus: A critical literature review. Biomed Res Int 2019;2019:8142368. 10.1155/2019/8142368</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/8142368</ArticleId><ArticleId IdType="pmc">PMC6668536</ArticleId><ArticleId IdType="pubmed">31396534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mouries-Martin S, Dorgham K, et al. . Monitoring disease activity in systemic lupus erythematosus with single-molecule array Digital enzyme-linked immunosorbent assay Quantification of serum interferon-&#x391;. Arthritis Rheumatol 2019;71:756&#x2013;65. 10.1002/art.40792</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40792</ArticleId><ArticleId IdType="pubmed">30507062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Nakayamada S, Kubo S, et al. . Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis 2018;77:1354&#x2013;61. 10.1136/annrheumdis-2017-212652</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212652</ArticleId><ArticleId IdType="pubmed">29853448</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa I, Nakayamada S, Nakano K, et al. . Precision medicine using different biological Dmards based on characteristic phenotypes of peripheral T helper cells in Psoriatic arthritis. Rheumatology (Oxford) 2019;58:336&#x2013;44. 10.1093/rheumatology/key069</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key069</ArticleId><ArticleId IdType="pubmed">29618121</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S, Nakayamada S, Yoshikawa M, et al. . Peripheral Immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients. Arthritis Rheumatol 2017;69:2029&#x2013;37. 10.1002/art.40180</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40180</ArticleId><ArticleId IdType="pubmed">28605137</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, et al. . Efficacy and safety of Rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with Rituximab study. Arthritis Rheum 2012;64:1215&#x2013;26. 10.1002/art.34359</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. . Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med 2020;383:1117&#x2013;28. 10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Takeuchi T, Miyasaka N, et al. . Efficacy and safety of Rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol 2016;26:80&#x2013;6. 10.3109/14397595.2015.1060665</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14397595.2015.1060665</ArticleId><ArticleId IdType="pmc">PMC4732415</ArticleId><ArticleId IdType="pubmed">26054418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley MA, Jayne D, Ginzler EM, et al. . Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886&#x2013;95. 10.1056/NEJMoa1014460</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1014460</ArticleId><ArticleId IdType="pubmed">22087680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, et al. . Revision of the International society of Nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of health activity and Chronicity indices. Kidney Int 2018;93:789&#x2013;96. 10.1016/j.kint.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa M, Nakayamada S, Kubo S, et al. . Type I and II Interferons commit to abnormal expression of Chemokine receptor on B cells in patients with systemic lupus erythematosus. Clin Immunol 2019;200:1&#x2013;9. 10.1016/j.clim.2018.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.12.017</ArticleId><ArticleId IdType="pubmed">30576845</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavragani CP, Kirou KA, Seshan SV, et al. . Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations. Rheumatology (Oxford) 2022:keac641. 10.1093/rheumatology/keac641</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac641</ArticleId><ArticleId IdType="pmc">PMC10321084</ArticleId><ArticleId IdType="pubmed">36355567</ArticleId></ArticleIdList></Reference><Reference><Citation>Arazi A, Rao DA, Berthier CC, et al. . Publisher correction: the immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 2019;20:1404. 10.1038/s41590-019-0473-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0473-3</ArticleId><ArticleId IdType="pubmed">31409923</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas M, Seshan SV, Barisoni L, et al. . Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the renal pathology society. Kidney Int 2020;98:1120&#x2013;34. 10.1016/j.kint.2020.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.08.006</ArticleId><ArticleId IdType="pubmed">32866505</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, Muenz LR, Joyce KM, et al. . Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689&#x2013;95. 10.1038/ki.1984.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1984.75</ArticleId><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Rivera C, Zhao W, Yalavarthi S, et al. . Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix Metalloproteinase-2. Ann Rheum Dis 2015;74:1417&#x2013;24. 10.1136/annrheumdis-2013-204837</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204837</ArticleId><ArticleId IdType="pmc">PMC4143484</ArticleId><ArticleId IdType="pubmed">24570026</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, et al. . Phase II randomised trial of type I interferon inhibitor Anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022;81:496&#x2013;506. 10.1136/annrheumdis-2021-221478</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>Larosa M, Zen M, Gatto M, et al. . IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med (Maywood) 2019;244:42&#x2013;51. 10.1177/1535370218824547</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370218824547</ArticleId><ArticleId IdType="pmc">PMC6362534</ArticleId><ArticleId IdType="pubmed">30664357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Nakayamada S, Kubo S, et al. . Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and Activators of transcription 3 in lupus patients. Rheumatology (Oxford) 2020;59:3058&#x2013;69. 10.1093/rheumatology/keaa176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa176</ArticleId><ArticleId IdType="pubmed">32375179</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Sun X, Wu S, et al. . Interleukin-12 exacerbates symptoms in an MRL/Mpj-Faslpr mouse model of systemic lupus erythematosus. Exp Ther Med 2021;21:627. 10.3892/etm.2021.10059</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10059</ArticleId><ArticleId IdType="pmc">PMC8082580</ArticleId><ArticleId IdType="pubmed">33936283</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci M, Lombardi L, Richards HB, et al. . Overexpression of Interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 2008;154:247&#x2013;54. 10.1111/j.1365-2249.2008.03758.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2008.03758.x</ArticleId><ArticleId IdType="pmc">PMC2612719</ArticleId><ArticleId IdType="pubmed">18795942</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Kalunian KC, D&#xf6;rner T, et al. . Phase 3, Multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of Ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis 2022;81:1556&#x2013;63. 10.1136/ard-2022-222858</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222858</ArticleId><ArticleId IdType="pmc">PMC9606504</ArticleId><ArticleId IdType="pubmed">35798534</ArticleId></ArticleIdList></Reference><Reference><Citation>Suso JP, Posso-Osorio I, Jim&#xe9;nez CA, et al. . Profile of BAFF and its receptors&#x2019; expression in lupus nephritis is associated with pathological classes. Lupus 2018;27:708&#x2013;15. 10.1177/0961203317739132</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317739132</ArticleId><ArticleId IdType="pubmed">29087261</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagafuchi Y, Shoda H, Fujio K. Immune profiling and precision medicine in systemic lupus erythematosus. Cells 2019;8:140. 10.3390/cells8020140</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8020140</ArticleId><ArticleId IdType="pmc">PMC6406577</ArticleId><ArticleId IdType="pubmed">30744169</ArticleId></ArticleIdList></Reference><Reference><Citation>Itotagawa E, Tomofuji Y, Kato Y, et al. . SLE stratification based on BAFF and IFN-I Bioactivity for Biologics and implications of BAFF produced by glomeruli in lupus nephritis. Rheumatology (Oxford) 2023;62:1988&#x2013;97. 10.1093/rheumatology/keac528</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac528</ArticleId><ArticleId IdType="pmc">PMC10152287</ArticleId><ArticleId IdType="pubmed">36094336</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>